XML 33 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Other Balance Sheet Information
 9 Months Ended
Jun. 26, 2021
Balance Sheet Related Disclosures [Abstract]  
Other Balance Sheet Information Other Balance Sheet Information
June 26,
2021		September 26,
2020
Inventories
Raw materials$159.4 $152.3 
Work-in-process58.5 46.5 
Finished goods285.0 196.3 
$502.9 $395.1 
Property, plant and equipment
Equipment$541.5 $460.7 
Equipment under customer usage agreements446.0 456.8 
Building and improvements187.9 167.3 
Leasehold improvements48.0 44.3 
Land41.4 40.7 
Furniture and fixtures16.9 16.1 
Right of use assets8.5 — 
$1,290.2 $1,185.9 
Less – accumulated depreciation and amortization(739.1)(694.4)
$551.1 $491.5 
In September 2020 and October 2020, the Company received grants of $7.6 million and $119.3 million, respectively, from the Department of Defense Joint Acquisition Task Force ("DOD") to expand production capacity for the Company's two SARS-CoV-2 assays. These grants are specifically to fund the capital equipment and labor investments needed to increase manufacturing capacity to enable the Company to provide a certain amount of COVID-19 tests per month for the U.S. market. The Company is accounting for the funds received under these grants as a reimbursement of the purchased capital equipment. The DOD retains title to assets purchased under the agreement, and title is transferred to the Company upon meeting certain milestones of the manufacturing efforts. In the current three and nine month periods, the Company received $8.3 million and $19.4 million, respectively, from the DOD under these grants which has been recorded as a reduction of the cost basis of the purchased equipment.